Sales of generics are expanding rapidly, with some large therapy areas becoming predominantly generic and others heading that way. We provide a clear picture of the generics market, based on consistent benchmarks and clarity on the underlying trends driving sector growth.
Succeeding in a predominantly generic marketplace brings unique challenges. In volume terms, generics already represent the largest segment of the pharmaceutical market in major markets -- and their dominance will only increase. Globally, generics are growing at twice the rate of brands and, in Europe, generics make up almost 50 percent of volume sales.
Our insights are used by generics and pharmaceutical manufacturers alike to guide decision-making in areas such as geographic expansion, portfolio optimization, lifecycle management and new technologies. We offer a range of information, publications and analytical services to help healthcare leaders understand the protected, unprotected, biosimilar and biologic markets and make more informed business decisions.
Key Generic Offerings From IMS Health
For the latest on the price volume dilemma in Asia Pacific—and how generics play in the mix—see 'Our Latest Thinking' by IMS Consulting Group.